CytomX Therapeutics to Announce Third Quarter 2020 Financial Results
29 Octubre 2020 - 6:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, plans to report second quarter
2020 financial results on Thursday, November 5, 2020, after the
close of U.S. markets. Following the announcement, the company will
host a conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT to
discuss the results.
Participants may access the live audio webcast of the
teleconference from the “Investors & News” section of CytomX’s
website at http://ir.cytomx.com/. Please access the website 15
minutes prior to the start of the call to download and install any
necessary audio software.
Audio Conference Call:
|
U.S. Dial-in
Number: |
(877)
809-6037 |
|
|
|
|
International Dial-in Number: |
(615) 247-0221 |
|
|
|
|
Conference ID: |
6705899 |
An archived webcast replay will be available on the Company's
website from November 5, 2020, until November 12, 2020.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company with a
vision of transforming lives with safer, more effective therapies.
We are developing a novel class of investigational antibody
therapeutics, based on our Probody® technology platform, for the
treatment of cancer.
Probody therapeutics are designed to remain inactive until they
are activated by proteases in the tumor microenvironment. As a
result, Probody therapeutics are intended to bind selectively to
tumors and decrease binding to healthy tissue, to minimize toxicity
and potentially create safer, more effective therapies. As leaders
in the field, our innovative technology is designed to turn
previously undruggable targets into druggable targets and to enable
more effective combination therapies. CytomX and its partners,
comprised of leading biotechnology and pharmaceutical companies,
have developed a robust pipeline of potential first-in-class
therapeutic candidates against novel, difficult to drug targets and
potential best-in-class immunotherapeutic candidates against
clinically validated targets. The CytomX clinical stage pipeline
includes first-in-class product candidates against previously
undruggable targets, including a CD166-targeting Probody drug
conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting
Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets that are considered to be
inaccessible to conventional antibody drug conjugates due to their
presence on many healthy tissues. The CytomX clinical stage
pipeline also includes cancer immunotherapeutic candidates against
validated targets such as our wholly owned anti-PD-L1 Probody
therapeutic, CX-072, and the CTLA-4-targeting Probody therapeutics,
BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb.
CytomX has strategic drug discovery and development collaborations
with AbbVie, Amgen, Astellas and Bristol Myers Squibb. For
additional information about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.Probody
is a U.S. registered trademark of CytomX
Therapeutics, Inc.Investor and Media Contact:Stern
Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024